Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Subscribe To Our Newsletter & Stay Updated
